A dose-finding study of the safety of gemtuzumab ozogamicin as a single agent treatment of patients with relapsed acute myelogenous leukemia after autologous or allogenic hematopoietic stem cell transplant
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2005
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 05 Sep 2005 New trial record.